(Total Views: 888)
Posted On: 12/02/2023 10:53:26 AM
Post# of 154646
https://register.gotowebinar.com/recording/11...4503440044
Dr Jay webinar. Must hear report from our ceo. Highlights::
HIV will be next study. Due to FDA interest and prudent use of very limited financial ability.
Not many bites at the apple left in cydy.
Nash and cancer studies will require partnership.
HIV study results must not be ambiguous.
FDA will likely lift hold. Within weeks to month.
FDA responded positively to the HIV amulatorysubgroup population study choice by CYDY.
Patent protection out to 2030 / 2040.
Dr. Jay regards LL as an immune modulator. (not an anti viral)
Dr. Jay is not taking a salary as of yet. Options open for him and cydy.
Hoping to create a monthly dose of LL which will significantly increase market opportunity.
Dr Jay webinar. Must hear report from our ceo. Highlights::
HIV will be next study. Due to FDA interest and prudent use of very limited financial ability.
Not many bites at the apple left in cydy.
Nash and cancer studies will require partnership.
HIV study results must not be ambiguous.
FDA will likely lift hold. Within weeks to month.
FDA responded positively to the HIV amulatorysubgroup population study choice by CYDY.
Patent protection out to 2030 / 2040.
Dr. Jay regards LL as an immune modulator. (not an anti viral)
Dr. Jay is not taking a salary as of yet. Options open for him and cydy.
Hoping to create a monthly dose of LL which will significantly increase market opportunity.
(19)
(0)
